WASHINGTON (CBS.MW) -- Mylan Laboratories (MYL) , responding to the latest in a series of letters from investor Carl Icahn, reasserted its position that acquiring King Pharmaceuticals (KG) is in the long-term interest of the generic drugmaker and its 